

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Early Moves: A protocol for a population-based prospective cohort study to identify biomarker of cognitive impairment in infants.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041695
Article Type:	Protocol
Date Submitted by the Author:	17-Jun-2020
Complete List of Authors:	<p>Elliott, Catherine ; Curtin University, School of Occupation Therapy, Social Work and Speech Pathology Alexander, Caroline; Curtin University, School of Occupational Therapy, Social Work and Speech Pathology Salt, Alison; Perth Children's Hospital, Paediatric Rehabilitation Spittle, Alicia; The University of Melbourne Department of Physiotherapy, Physiotherapy; Murdoch Childrens Research Institute, Victorian Infant Brain Studies Boyd, Roslyn; The University of Queensland, Queensland Cerebral Palsy and Rehabilitation Research Centre; The University of Queensland, Queensland Children's Medical Research Institute Badawi, Nadia; Children's Hospital at Westmead, Neonatology Morgan, Catherine; The University of Sydney, Cerebral Palsy Alliance Silva, Desiree; The University of Western Australia Geelhoed, Elizabeth; The University of Western Australia, School of Population Health Ware, Robert; Griffith University, Menzies Health Institute Queensland Ali, Alishum; Curtin University McKenzie, Anne; The University of Western Australia Bloom, David; Harvard University T H Chan School of Public Health Sharp, Mary; The University of Western Australia, School of Paediatrics and Child Health Ward, Roslyn; Curtin University, School of Occupation Therapy, Social Work and Speech Pathology Bora, Samudragupta; Mater Research, Mothers, Babies and Women's Health Program Prescott, Susan; The University of Western Australia Woolfenden, Susan ; Local Government and Shires Association of NSW, ; University of New South Wales, Le, Vuong; Deakin University Davidson, Sue-Anne; Perth Children's Hospital, Paediatric Rehabilitation Thornton, Ashleigh; University of Western Australia, Jensen, Lynn; Curtin University Amery, Natasha; Curtin University, School of Occupational Therapy, Social Work and Speech Pathology Early Moves Clinical Working Group, -; Perth Children's Hospital Valentine, Jane; Perth Children's Hospital, Paediatric Rehabilitation</p>
Keywords:	Developmental neurology & neurodisability < PAEDIATRICS, Community

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	child health < PAEDIATRICS, PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Early Moves: A protocol for a population-based prospective cohort study to identify early biomarker of cognitive impairment in infants.

Word Count: 4,485 words

Number of Figures: 1

Number of Tables: 1

Authors:

Elliott, C; Curtin University

Alexander, C; Curtin University

Salt, A; Perth Children's Hospital

Spittle, A; University of Melbourne

Boyd, RN; The University of Queensland

Badawi, N; CP Alliance Research Institute, Grace Centre for Newborn Intensive Care, The Children's Hospital at Westmead, University of Sydney

Morgan, C; CP Alliance Research Institute, University of Sydney

Silva, D; University of Western Australia

Geelhoed, E; University of Western Australia

Ware, RS; Menzies Health Institute Queensland, Griffith University

Ali, A; Curtin University

McKenzie, A; University of Western Australia

Bloom, D; Harvard University

Sharp, M; University of Western Australia

Ward, R; University of Notre Dame

Bora, S; Mothers, Babies and Women's Health Program, Mater Research Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia

Prescott, S; University of Western Australia

Woolfenden, S; University of New South Wales

Le, V; Deakin University

Davidson, S; Perth Children's Hospital

Thornton, A; Perth Children's Hospital, University of Western Australia

Jensen, L; Curtin University

Amery, T; Curtin University

1
2
3 Early Moves Clinical Working Group¹
4

5 Valentine, J; Perth Children's Hospital
6
7

8
9 Corresponding Author: Jane Valentine. Jane.valentine@health.wa.gov.au
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 ¹ Early Moves Clinical Working Group is comprised of Jane Valentine (Perth Children's Hospital),
53 Alison Salt (Perth Children's Hospital), Desiree Silva (University of Western Australia), Caroline
54 Alexander (Curtin University), Natasha Amery (Curtin University), Arlette Coenen (Curtin University),
55 Rosalie Morie (Perth Children's Hospital), Jennifer Moore (Perth Children's Hospital), Madeleine
56 OConnor (Ramsay Healthcare Joondalup Health Campus) Ravisha Srinivasjois (Ramsay Healthcare
57 Joondalup Health Campus), Jason Tan (Perth Children's Hospital), Elayne Downie (Telethon Kids
58 Institute), Ruth Last (Telethon Kids Institute), Mary Sharp (University of Western Australia), John
59 Wray (Health Department of Western Australia), Sue-Anne Davidson (Perth Children's Hospital) and
60 Ashleigh Thornton (Perth Children's Hospital)

Abstract:

Introduction:

The current traditional diagnostic pathways for cognitive impairment rarely identify babies at risk of cognitive impairment before 2 years of age. Without very early detection and timely targeted intervention, these children and their families have poorer health outcomes and do not reach their full life potential. *Early Moves* aims to identify early biomarkers, including General Movements (GMs), for babies at risk of cognitive impairment, allowing early intervention within critical developmental windows to enable these children to have the best possible start to life.

Method and analysis:

Early Moves is a double masked prospective cohort study that will recruit 3,000 babies. *Early Moves* will determine the diagnostic value of abnormal GMs (at writhing and fidgety age) for mild, moderate and severe cognitive delay at two-years measured by the Bayley-4. Parents will use a novel smart-phone app called Baby Moves to video their babies' GMs. Trained GMs assessors will be masked to any risk factors and assessors of the outcome will be masked to the GMs result. Automated scoring of GMs will be developed through applying machine-based learning to the data and the predictive value for an abnormal GM will be investigated. Screening algorithms for identification of children at risk of cognitive impairment, using the GM Assessment (GMA), and routinely collected social and environmental profile data will be developed to allow more accurate prediction of cognitive outcome at 2 years. A cost evaluation for GMA implementation in preparation for national implementation will be undertaken including exploring the relationship between cognitive status and health care utilisation, medical costs, health-related quality of life and caregiver burden.

Ethics and dissemination:

Ethics approval has been granted by the Medical Research Ethics Committee of Joondalup Health Services and the Health Service Human Research Ethics Committee (1902) of Curtin University (HRE2019-0739).

Trial registration number: ACTRN12619001422112

Article Summary

Strengths and limitations of this study:

- This is the first population based prospective cohort study investigating the utility of the General Movements assessment as a biomarker to identify children with cognitive impairment during early infancy.
- This is the first study to explore the feasibility of using smart phone app based video collection of GMs in a large population.
- This study will develop automated scoring of the GMs using machine learning making wide scale screening possible in the future.
- This study will combine the GMA outcome, with routinely collected demographic and health data to develop a screening algorithm for identification of infants at risk of cognitive impairment.
- This study is limited by its exclusion of families with limited English language.

Key Words (MeSH Terms):

- Cognitive Dysfunction
- Infant
- Child Development
- Cohort Studies
- Neonatal Screening

Introduction

Neurodevelopmental disorders (NDD) result from changes in the brain that lead to a delay in skill development, including cognitive, language and motor impairments. The lifelong impact of NDD has enormous personal and financial burden on the individual, their family and the community. In Australia, the cost of intellectual disability (also referred to as cognitive impairment) alone, is estimated to be \$14,720 billion annually [1].

The first two years of life are a critical period for motor and cognitive development due to the timing of corticospinal tract development and the plasticity mechanisms at work in the infant's brain [2]. Thus, the earlier cognitive impairment can be detected, the greater the potential benefits of ensuing early interventions for optimising neuroplasticity, preventing or ameliorating neurodevelopmental disorders and enhancing parental wellbeing. At present it is difficult to accurately diagnose infants at risk of cognitive impairment [3-6]. Considerable delay between parents' first concerns and confirmation of a diagnosis is often reported [7]. This is more pronounced for those residing outside major centres, with a known health inequality in regional and rural Australia, and in poorly served outer metropolitan areas of large cities [8].

General Movements (GMs) are a distinct spontaneous movement pattern evident in babies before and after birth[9], with writhing GMs observed in utero up to 8 weeks post-partum, and fidgety GMs which are present from 8 to 20 weeks' post-term [10]. General Movements are now recognised as a sensitive tool for providing information on the health of a baby's brain function [11, 12]. The absence of fidgety GMs is the best predictor of cerebral palsy in high-risk infants, with pooled estimates of 98% sensitivity and 91% specificity [12].

While the GMs are accurate for predicting motor impairment, recent evidence suggests GMs may be a biomarker for identifying cognitive impairment in preterm infants [13, 14]. In two systematic reviews higher risk of cognitive impairment was associated with persistence of abnormal writhing GMs until 8 weeks after term and with monotonous movement sequences and postural abnormalities at 3-5 months. Further, the developmental quotient at 2-3 years of children born preterm, with abnormal writhing GMs at 1 month post-term, was lower than gestation and age matched infants with normal writhing GMs [14].

1
2
3 Abnormal fidgety GMs in preterm infants was also found to be associated with a score
4 on average eight points lower on the Bayley Scales of Infant and Toddler
5 Development–Second Edition at two years of age compared to those with normal
6 fidgety GMs [15]. This difference in cognition was greater when the children were
7 reassessed at age four years on the Differential Ability Scale [15]. These findings
8 indicate that abnormal spontaneous movement patterns, at both the writhing and
9 fidgety stages, may presage later cognitive impairment. The majority of this evidence
10 however exists in preterm and high-risk infants; there is a paucity of information for
11 healthy term infants.
12
13

14
15
16
17
18
19 More detailed scoring of the GM, in which every movement criterion is given a score
20 [16] is known as the GM Optimality Score (GMOS) at the writhing age [17], and the
21 Motor Optimality Score (MOS) at the fidgety age [18]. A higher score represents more
22 optimal movements. In a study of 40 extremely preterm infants, only six out of 33
23 infants that showed normal fidgety movements, were found to have the highest MOS
24 score possible [19], highlighting the increased sensitivity of optimality scoring
25 compared to global GMA.
26
27

28
29
30
31
32 Should GMs be shown to be an early biomarker for cognitive impairment, there are
33 still barriers to implementing GMA as a population level screening tool. These barriers
34 include access to trained assessors in many locations, and the cost involved in
35 videoing of the infant. To overcome these barriers, a smart-phone app called Baby
36 Moves has been developed allowing families or health professionals to record and
37 upload GM recordings directly [20], removing the need for in-person appointments.
38
39

40
41
42
43 The use of machine based movement recognition, aimed at automatic detection,
44 classification and quality assessments of limb movements has the potential to further
45 reduce the time and financial costs of GM assessments. This approach has been
46 explored by a number of researchers aiming to automate reporting of fidgety GMs [21-
47 26]. Results suggest automated readings of fidgety movements are feasible, reporting
48 sensitivity and specificity of 79-85% and 63-71% respectively [21-23]. Automated
49 video analysis may provide a low-cost, high sensitivity approach by combining the
50 sensitivity of advanced machine classification as a primary screening mechanism, and
51 the specificity of human expert opinion on videos classified as high risk by the
52 automation.
53
54
55
56
57
58
59
60

1
2
3 It is known that a child's biological and environmental profile is related to
4 developmental outcomes [27-29]. A number of protective and risk factors, particularly
5 birth weight, gender and prematurity, and maternal age are routinely collected and
6 documented. Applying a bioecological model [30] to explore developmental
7 vulnerability using routinely collected data, in conjunction with GM assessments may
8 provide a stronger predictive tool than GM's alone creating a robust and meaningful
9 screening tool [27].
10
11
12
13
14

15
16 Identification of an early biomarker, along with the development and validation of an
17 accessible affordable and scalable screening tool, for the early identification of
18 cognitive impairment would allow a greater number of infants to receive effective early
19 interventions during the critical window of brain development: an advantage to the
20 child, family and greater society.
21
22
23

24
25 *"The economic benefit [of early detection and intervention] could be great, but the*
26 *benefit to the families is priceless"*
27
28

29 *-Kids Rehab WA Consumer group member*
30
31

32 **Aims and Hypothesis**

33

34 Phase One – GMA as a biomarker

35

36
37 The primary aim of phase one is to determine the diagnostic value of abnormal GMs
38 for cognitive delay at two-years.
39
40

41 It is hypothesised that abnormal GMs will be predictive of cognitive delay at two years.
42 As this is the first study to look at the predictive ability of GMA for cognitive delay or
43 impairment in a large birth cohort of majority low risk infants, we have insufficient data
44 to hypothesise the diagnostic test accuracy.
45
46
47

48 The secondary aim of phase one is to develop automated scoring of the GMA through
49 applying machine based learning to the data. It is hypothesised that automated scoring
50 of GMA will have >90% specificity and >85% specificity to detect GM abnormalities,
51 with lower accuracy for optimality scores.
52
53
54

55 Phase Two – Screening algorithm

56
57
58
59
60

1
2
3 The primary aim of phase two is to develop screening algorithms for identification of
4 children at risk of cognitive impairment, using the GMA, and routinely collected social
5 and environmental profile data.
6
7

8
9 It is hypothesised an algorithm of early child, family and societal risk factors and GMA
10 and optimality scores, will be a more accurate predictor of cognitive status at 2 years
11 corrected age than GMA or optimality scores alone.
12
13

14 15 Phase Three – Cost and economic evaluations

16
17 The primary aim of phase three is to conduct a cost evaluation for GMA
18 implementation from the perspective of the funder in preparation for national
19 implementation.
20
21

22
23 The secondary aim of phase three is to assess the relationship between cognitive
24 status and health care utilisation, medical costs, health-related quality of life and
25 caregiver burden.
26
27

28
29 It is hypothesised cognitive impairment will predict; higher health care utilisation and
30 direct medical costs, poorer health-related quality of life and higher caregiver burden.
31
32

33 34 **Methods**

35 36 **Study Design**

37
38 This study is a double-masked, prospective cohort study of 3,000 babies. The
39 methodological design of this cohort study has been informed by the 2007
40 “Strengthening the Reporting of Observational Studies in Epidemiology” (STROBE)
41 checklist for cohort studies [31]. The methodological design of phase one (a study of
42 diagnostic test accuracy), was informed by the 2015 “Standard for Reporting of
43 Diagnostic Accuracy Studies” (STARD) checklist [32].
44
45
46
47
48

49 50 **Setting**

51
52 This study is a sub-study of the ORIGINS project, a major Western Australian cohort
53 study of 10,000 families, with detailed data and sample collection,
54 including environmental and biological profiling on 5,000 families. It is the largest
55 representative sample of Australian infants (preterm and term born) [33]. Participants
56 are recruited in to one of two arms of the ORIGINS study:
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
1. Non-active participants: Consent to use of de-identified databank and biobank information available via routine hospital data collections and data linkage to both WA and Australian Government Data.
 2. Active Participants: In addition to the above, additional lifestyle and environmental data via online questionnaires, biological sampling and infant follow-up at specific time points which is not part of standard care, are collected.

Recruitment

Early Moves will recruit a total of 3,000 infants who are enrolled in The ORIGINS Project between November 2019 and December 2022, with a least 2,000 infants from the Active Participant arm of ORIGINS. Recruitment can occur at any time, up until discharge from hospital after the birth of the baby. To reduce risk of self-selection bias on the basis of birth experience, antenatal recruitment will targeted where possible (Figure 1). Timing of consent relative to birth will be recorded.

Inclusion Criteria

- a) Mother intending on birthing/have recently birthed at Joondalup Health Campus between 2019 and 2022
- b) Enrolled in the ORIGINS project

Exclusion Criteria

- a) Babies enrolled in an ORIGINS intervention study that has a primary cognitive or language outcome

Masking

The assessors will be masked to baby's gestation at birth; birth, medical and social history and the results of any of the ORIGINS or *Early Moves* outcomes. Abnormalities in serial GM assessments are known to be predictive of cerebral palsy, so in cases where abnormalities are identified, the participants will be notified and referred to the appropriate clinical services for further investigation and management. Based on rate of cerebral palsy in Australia of 1.4 per 1000 live births [34], we anticipate to identify approximately 5 cases of cerebral palsy, where parents will be unmasked to GM outcomes as per above protocol.

Bias

1
2
3 As a prospective cohort study selection bias is minimised as participants will enrol prior
4 to or very soon after the birth of the baby. The ORIGINS project [33] has a number of
5 effective strategies in place to reduce loss to follow up. The Ages and Stages
6 Questionnaire, a developmental screening tool administered as part of ORIGINS [33],
7 will be used to explore study bias for any children lost to follow up in the *Early Moves*
8 study within the active cohort.
9

14 Phase One: Predictive Variables

16 General Movements will be obtained using the Baby Moves smartphone app. A 3
17 minute video is taken using the app with the baby lying on a plain, flat surface in an
18 awake, settled state. Videos are securely uploaded to the study database for remote
19 assessment by the GM assessors according to Prechtl's GMA, and calculation of
20 GMOS [16, 17] and MOS [16, 18]. The Baby Moves app has been successfully piloted
21 at the fidgety period on 446 infants to determine feasibility [20, 35], with 69.9% - 82.7%
22 of the videos taken by families scorable [35]. This study seeks to reduce the proportion
23 of un-scorable videos to 15% by employing personalised training and parental
24 education, instructional films and the use of e-reminders of upcoming and currently
25 due videos, and phone support. Further, as this study commences with the first video
26 made within 2 weeks post-term rather than 12 weeks post-term, we anticipate families
27 will be more engaged with the study compared with early studies using the Baby
28 Moves app. Videos received will be reviewed within two weeks of submission to check
29 for quality, and families will be contacted via phone if the video is un-scorable.
30 Collection of two videos within each time period further increases the likelihood of one
31 scorable video being attained within each time period.
32

33 Remote GMA will be conducted for each of the two time periods, (Figure 1). For the
34 purpose of exploring the predictive ability of GM on cognitive impairment, assessment
35 will be conducted on the first video, with the second video used if a) the first is not
36 scorable, or b) there is uncertainty around classification and further video footage is
37 required to make a final decision.
38

- 39 1. Time-period 1 "Writhing" – videos collected at 1 to 2+6 and 3 to 4+6 weeks
40 post-term age. Movements will be classified, and GMOS calculated.
- 41 2. Time-period 2 "Fidgety" – videos collected at 12 to 13+6 and 14 to 16
42 +6 weeks post-term age. Movements will be classified and MOS calculated.
43

General Movement Fidelity

General Movement Assessments will be conducted by qualified and registered clinicians who have experience in reporting GMA's and have passed the advanced GMs course by the General Movements Trust. The assessors must have experience in clinical and research application of GM assessment prior to involvement in the study.

Each GM and GMOS/MOS assessment will be conducted by two individual assessors. If there is disagreement between the two assessors a third blinded, experienced GM Instructor (ASp or CM), will make the final decision. Disagreement is defined as difference in GM categorical assessment, or optimality scores of more than five point difference [36].

The interrater reliability of the three assessors for GMA will be accepted as "almost perfect" ($\geq 82\%$ of data are reliable, with Cohen's Kappa > 0.9). Interrater reliability and agreement for GMOS and MOS will be accepted as "excellent reliability" (intraclass correlation coefficient of > 0.9 using two-way random effects ANOVA) [37]. This will be done by triple scoring the first 10 videos, then 10% (selected at random) of each block of 100 videos until criteria for reliability are met. To ensure reliability is maintained throughout the study, a random selection of 10 videos out of every 300 will be triple scored.

Automated reading of GMA

Advanced machine learning methods have been developed to classify and separate normal versus abnormal videotaped fidgety GM [35, 38]. Video recordings are processed using a pipeline of computer vision and machine learning techniques to predict GMA. Salient point detection (where the joints related to the GM of the infant are located and tracked in the video frames) is followed by extraction of the local motions of the joints into feature vectors. These feature vectors are automatically classified using our anomaly detection algorithm developed during pilot work [38, 39]. Based on a k – nearest neighbour classification approach on 265 video recordings of babies, and a feature based on the histogram of the optical flow, the accuracy for automated GMA is 72.9% [39].

Table 1 Source of routinely collected demographic and health factors used for the development of screening algorithms in Phase Two. Factors are grouped according to levels, employing a bioecological model of child development. JHC: Joondalup Health Campus

Phase One: Primary Outcomes

The	Midwives Notification System	JHC Mother's Health Questionnaire
Cultural and Neighbourhood Factors		
Socioeconomic Index (SEIFA)	√	
Ethnicity	√	
Parent/Family Factors		
Marital status	√	√
Smoking during pregnancy	√	√
Alcohol consumption during pregnancy	√	√
Illicit drug use during pregnancy		√
Maternal Medical Conditions	√	
Maternal Mental Health Conditions		√
Perinatal Mental Health Risk Factors	√	
Child/Biological Factors		
Pregnancy complications	√	√
Family History of Developmental Difficulties		√
Method of Birth	√	
Complications of labour and birth	√	
Gender	√	
Infant Weight	√	
Resuscitation	√	
Estimated Gestation	√	
Birth defects	√	
Birth trauma	√	
Special care number of days	√	
Plurality	√	

Bayley Scales of Infant and Toddler Development- 4 (Bayley-4) [40] is the most frequently used test in infant developmental assessments. Bayley-4 cognitive and language score is the primary outcome at 2 years corrected age. Cognitive delay will be defined as mild (when the Bayley-4 cognitive and language score falls between 1

1
2
3 and 2SD below the Australian mean), moderate (score between 2 and 3SD below the
4 Australian mean) or severe (score more than 3SD below the Australian mean) [41].
5 Children unable to complete psychological testing because of presumed severe
6 cognitive delay will be assigned a score of -4 SD. If babies score <-2SD on the Bayley-
7 4 across any domain, they will be referred to the appropriate developmental services
8 for further investigation and management.
9
10
11
12

13 14 Phase Two: Screening Algorithms

15
16 Screening algorithms for identifying children requiring early intervention for cognitive
17 delay will be developed using data available from the Joondalup Health Campus (JHC)
18 Mothers Health Questionnaire (routinely administered to all mothers intending to birth
19 a JHC), and the Midwives Notification System (Table 1). Linked data from the Western
20 Australian Register of Developmental Anomalies at age 1 year will be utilised.
21
22
23
24

25 Phase Three: Health Economics

26
27 Health care resources will be measured and standard cost sources will be used to
28 apply unit costs to resources. Costs will be standardised to a reference year and future
29 costs will be discounted according to standard practice. Resources and associated
30 costs will include GMA and Bayley-4. The cost of GMA will include ongoing cost of the
31 app and labour resources required for assessment of the videos. Health-related
32 resource use data collected will include screening assessments, therapy frequency
33 and duration (traditional/alternate), hospital admissions, GP and medical specialist
34 visits, medications and equipment. Data will be collected via the Health Resource use
35 (HRU) questionnaire [42], supplemented by consented access to individual hospital,
36 Medical Benefits Scheme (MBS) and Pharmaceutical Benefits
37
38
39
40
41
42
43

44
45 Scheme (PBS) records.

46
47 The *Carer Experience Scale (CES)* will be employed as a measure of caregiver
48 burden. This validated measure of care-related quality of life has six domains
49 (activities, support, assistance, fulfilment, control and relationship with the care
50 recipient) and takes approximately 3 minutes to complete [43]. The Carer Experience
51 Scale is scored from an algorithm derived from preferences of the general population
52 and can be used to value carer outcomes in economic evaluation using index values
53 [43].
54
55
56
57
58
59

60 Sample Size Estimation

1
2
3 *Early Moves* is a single masked prospective cohort study and will recruit 3,000 babies
4 sufficient to establish >90% sensitivity and >94% specificity (alpha 0.05 and assuming
5 actual sensitivity and specificity = 92.5% and 95%, 15% attrition, 15% non-readable
6 images). For secondary outcomes, there is sufficiently high power to detect even
7 small associations between early GM results and Bayley-4 interval scores at 2years.
8 For example if 90% of children have normal GMs as infants, the study is powered to
9 detect between group (GM normal vs abnormal) differences on the Bayley- 4
10 (cognitive and language) at 2 years of 3.5 points or greater with 90% power (assuming
11 alpha=0.05, and SD=15 points).
12
13
14
15
16
17
18

19 Statistical Analysis

20
21
22 Summary statistics will be described using either mean (standard deviation) or median
23 (25th-75th percentile) for continuous variables, according to distribution, or as
24 frequency (percentage) for categorical variables.
25
26

27 For Phase One, the primary aim will be assessed using standard diagnostic statistics
28 (e.g. sensitivity, specificity, predictive values, and likelihood ratios). The predictive
29 validity of the GM categorical classification will be established using logistic
30 regression. The diagnostic value of machine learning for identifying GM writhing and
31 fidgety categorical classification will be evaluated by determining the accuracy,
32 precision, recall and area under the curve (AUC) of both automated machine
33 assessment and machine-human hybrid assessment using the entire dataset of videos
34 (n=6000). An algorithm for early diagnosis of cognitive impairment will be developed
35 using logistic regression modelling, using variables from the GMOS/MOS, GMA
36 categorical classification. Variables will be entered using forward selection based on
37 the Wald statistic. Sensitivity and specificity of the regression model, with 95%
38 confidence intervals will be established.
39
40
41
42
43
44
45
46
47

48 For Phase Two, screening algorithms based on the association between
49 measurements recorded at birth or in infancy (e.g. GM category) and measurements
50 recorded at 2 years will be assessed using linear regression for interval outcome data,
51 logistic regression for binary outcome data, and Poisson regression for count outcome
52 data. Hierarchical mixed-effects models will be used with 'participant' included in the
53 model as a random effect in order to account for the non-independence of
54 observations from the same participant. Motor impairment will be tested as a
55
56
57
58
59
60

1
2
3 potentially confounding variable for all models. Variables will be selected for potential
4 inclusion in multivariable models based on univariable significance at the $p < 0.2$ level.
5
6 Multivariable models will be built in a step-wise manner with redundant variables
7 eliminated using Akaike's and Schwarz's Bayesian criteria. Interactions will be
8 investigated as appropriate.
9
10

11
12 For Phase Three, cost and economic evaluations will consider service use and service
13 costs. We will describe patterns of met and unmet need in the study children, and
14 indirect costs to families will be examined. Associations between costs and all other
15 outcome variables, including those related to cognitive outcome will be assessed, with
16 adjustment for confounders.
17
18

19 20 21 Ethics and dissemination 22

23
24 The ORIGINS Project (ref. #1440) and *Early Moves* (ref. #1902) has been approved
25 by the Human Research Ethics Committee of JHC. Participant information booklets
26 will be provided to all participants prior to entry into the study, and full written and
27 informed consent will be obtained from all participants.
28
29

30
31 A collaborative (push, pull, exchange) knowledge translation model has been adopted
32 in this study [44, 45]. Project investigators will champion knowledge translation across
33 five levels of Health: Consumer and Service Providers; Department; Program; and
34 Health Service Level. Specific knowledge translation strategies and skill building
35 activities will be targeted across the phases of the *Early Moves* Project, and in
36 consultation with our stakeholders. This will include, but are not limited to,
37 dissemination of findings to consumers and stakeholders via peer reviewed publication
38 of study results, plain language summaries, newsletter feedback and media case
39 studies, as well as presentations at key national and international conferences.
40
41

42 43 44 Public/patient involvement 45 46 47

48
49 Community engagement is at the core of the ORIGINS and *Early Moves* projects [33],
50 with the implementation of a collaborative model of involvement [46]. Community
51 members of a clinical consumer reference group were involved in the priority setting
52 for the study, specifically parents of children with cognitive impairment. When asked
53 whether they felt the study was important and worthwhile, the response was very
54 positive, e.g. "Yes, yes, yes. I don't understand why you wouldn't do it." The group
55
56
57
58
59
60

1
2
3 also endorsed time points, methods for collection of data and follow up protocols for
4 abnormal GMA results. Furthermore, ORIGINS has a dedicated community
5 stakeholder coordinator and 12 parents whom form a consumer reference group. This
6 ORIGINS consumer reference group has been involved in development of recruitment
7 and information and consent materials for *Early Moves*. Consumer and community
8 representation is also incorporated in the ORIGINS and *Early Moves* governance
9 structure.

10
11 Bidirectional, effective and continuous communication with consumers will guide
12 research directions, interpretation of findings and their implications for policy.
13

14 15 16 17 18 19 20 **Discussion**

21
22 At present, early intervention for cognitive impairment is hindered by the lack of early
23 biomarkers to allow accurate early diagnoses or risk identification to occur. *Early*
24 *Moves* aims to identify early biomarkers for babies at risk of cognitive impairment,
25 allowing early intervention within critical developmental windows to enable babies to
26 have the best possible start to life.
27

28
29 The study has a number of strengths. It is a well powered study with a population-
30 based sample. The recruitment during the antenatal period ensures self-selection bias
31 is minimised where it relates to the birth experience (e.g. prematurity; late pregnancy
32 or birth complications). The assessment variables utilised in this study have proven
33 reliability and validity. As a sub-project of the ORIGINS project, *Early Moves* will have
34 access to biobank data, to generate a detailed biological and environmental risk
35 profile, to inform predictive algorithms, and investigate links between cognitive
36 impairment and biological and environmental factors. The study has strong consumer
37 involvement and an embedded knowledge translation plan which will help guide and
38 facilitate the translation of research findings in to clinical practice.
39

40
41 A potential limitation is that the final outcome measure is conducted at two years.
42 Research in premature babies shows the association between abnormal GMs and
43 cognitive impairment is weaker at 2 years compared to 4 years [15]. The cohort will
44 however be followed until age 5 years as part of the ORIGINS project, with later
45 assessments to include developmental assessments such as Ages and Stages
46 questionnaires and linkage to the Australian Early Development Census (AEDC)
47 providing data on early childhood development at entry to the first year of full time
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 school. The AEDC is an Australian wide data collection conducted by teachers using
4 the Australian version of the Early Development Instrument. Exclusion of families who
5 do not have sufficient English to complete standardised questionnaires is also a
6 limitation. This exclusion criterion has been set by the ORIGINS study, which does not
7 allow the recruitment of mothers with insufficient English to provide consent if reliance
8 on an interpreter is required. This study is also potentially limited by the single site
9 recruitment. Demographic data will be available to aid in the interpretation of
10 generalisability to other populations.
11
12

13
14
15
16
17 *Early Moves* will provide novel care models in rural and remote communities through
18 the use of smart phone technology and machine based learning, facilitating the
19 feasibility of app-based GM assessments as a population wide assessment tool.
20 Through combining automated app-based GM assessments with routinely collected
21 risk and protective factors, employing a bioecological model of development, *Early*
22 *Moves* recognizes the complex interplays of risk and protective factors to create a
23 robust screening tool for cognitive impairment in infants. Inclusion of health economics
24 evaluation will further enhance the potential for this technology to be translated in to
25 clinical care.
26
27
28
29
30
31
32

33 Acknowledgement

34
35
36 The authors would like to thank Svetha Venkatesh from Deakin University for her
37 contribution to this study, and The ORIGINS Project Team, including, but not limited
38 to Erika Haggeman, Jackie Davis, and Lucy Giggs for their contribution and support.
39
40

41 Conflict of Interest

42
43
44 None declared.
45

46 Funding

47
48
49 Supported by a Clinical Trials and Cohort Study Grant awarded by the National Health
50 and Medical Research Council, a Project Grant awarded by the Research Foundation,
51 Cerebral Palsy Alliance, a Project Grant awarded by the WA Child Research
52 Foundation, and a Project Grant awarded by the Perth Children's Hospital Foundation.
53
54
55

56 Author Contributions

57
58
59
60

1
2
3 CE and JV are the chief investigators and together with CA, ASa, ASp, RNB, NB, CM,
4 DS, EG, and RSW designed established and achieved funding for the research study.
5 AA, AM, DB, MS, RW, SB, SP, SW, VL, SD, AT, LJ, NA, and the Early Moves Clinical
6 Working Party (EMCWP) also contributed to study design. CE, JV and CA are
7 responsible for ethics applications and reporting. CA, DS, and SP are responsible for
8 recruitment. CE, JV, CA, ASa supervise the data collection and implementation of
9 training. CE, JV, ASa, AS, CM, MS, NA and EMCWP are responsible for design and
10 implementation of GM outcomes. NB, CM and VL are responsible for design and
11 implementation of machine learning outcomes. AT, AM, RW, SD and AA are
12 responsible for design and implementation of consumer engagement outcomes. EG
13 is responsible for design and implementation of health economics outcomes. SW, DS
14 and CA are responsible for design and implementation of routinely collected screening
15 outcomes. JV, ASa, and SB are responsible for design and implementation of
16 developmental outcomes. CE, JV, CA, ASa, ASp, RNB, NB, CM, DS, EG, and RSW
17 will take lead roles in preparation for publications on the clinical outcomes of the study.
18 RSW will take on a lead role of statistical analysis for the study. All authors contributed
19 to the preparation of this manuscript and have approved the final version.
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Data statement

34
35 De-identified individual participant data that underlie the results published in articles
36 resulting from this study will be made available to researchers on a case by case basis,
37 beginning 6 months and ending 5 years following the relevant article publication. Data
38 will be made available to researchers who provide a methodologically sound proposal
39 with appropriate research governance and ethics approvals, for the purposes of
40 achieving aims of approved proposal of for use in meta-analysis. Proposals should be
41 directed to Catherine Elliott Catherine.elliott@curtin.edu.au
42
43
44
45
46
47


48 References

- 49 1. Doran, C., et al., *How much does intellectual disability really cost? First*
50 *estimates for Australia*. J Intellect Dev Disabil., 2012. **37**(1): p. 42-49.
- 51 2. Williams, P. and J. Martin, *Motor cortex activity organizes the developing*
52 *rubrospinal system*. Journal of Neuroscience, 2015. **35**(39): p. 13363-13374.
- 53 3. Peyton, C., M.D. Schreiber, and M.E. Msall, *The Test of Infant Motor*
54 *Performance at 3 months predicts language, cognitive, and motor outcomes*
55 *in infants born preterm at 2 years of age*. Dev Med Child Neurol, 2018. **60**(12):
56 p. 1239-1243.
57
58
59
60

4. Morgan, C., *Towards more accurate prognostication after preterm birth*. *Developmental Medicine & Child Neurology*, 2018. **60**(12).
5. Wong, H.S., et al., *Developmental assessments in preterm children: A meta-analysis*. *Pediatrics*, 2016. **138**(2).
6. van't Hooft, J., et al., *Predicting developmental outcomes in premature infants by term equivalent MRI: systematic review and meta-analysis*. *Systematic Reviews*, 2015. **4**(1).
7. Scherzer, A., et al., *Global perspective on early diagnosis and intervention for children with developmental delays and disabilities*. *Dev Med Child Neurol.*, 2012. **54**(12): p. 1079-1084.
8. Australian Institute of Health and Welfare, *A picture of Australia's children 2012*, AIHW, Editor. 2012, AIHW: Canberra.
9. Prechtl, H.F., et al., *An early marker for neurological deficits after perinatal brain lesions*. *The Lancet*, 1997. **349**(9062): p. 1361-1363.
10. Ferrari, F., et al., *Prechtl's method on the qualitative assessment of general movements in preterm, term and young infants*. 2004: Mac Keith Press.
11. Burger, M. and Q.A. Louw, *The predictive validity of general movements – A systematic review*. *European Journal of Paediatric Neurology*, 2009. **13**(5): p. 408-420.
12. Bosanquet, M., et al., *A systematic review of tests to predict cerebral palsy in young children*. *Developmental Medicine & Child Neurology*, 2013. **55**(5): p. 418-426.
13. Peyton, C. and C. Einspieler, *General Movements: A Behavioral Biomarker of Later Motor and Cognitive Dysfunction in NICU Graduates*. *Pediatric annals*, 2018. **47**(4): p. e159-e164.
14. Einspieler, C., et al., *The General Movement Assessment helps us to identify preterm infants at risk for cognitive dysfunction*. *Frontiers in Psychology*, 2016. **7**(406).
15. Spittle, A.J., et al., *General movements in very preterm children and neurodevelopment at 2 and 4 years*. *Pediatrics*, 2013: p. peds. 2013-0177.
16. Einspieler, C., et al., *Prechtl's method on the qualitative assessment of general movements in preterm, term and young infants*. *Clinics in Developmental Medicine*. Vol. 167. 2004: Mac Keith Press.
17. Einspieler, C., et al., *The general movement optimality score: a detailed assessment of general movements during preterm and term age*. *Developmental Medicine & Child Neurology*, 2016. **58**(4): p. 361-368.
18. Einspieler, C., et al., *Cerebral palsy: Early markers of clinical phenotype and functional outcome*. *Journal of Clinical Medicine*, 2019. **8**.
19. Sharp, M., A. Coenen, and N. Amery, *General movement assessment and motor optimality score in extremely preterm infants*. *Early human development*, 2018. **124**(1): p. 38 - 41.
20. Spittle, A., et al., *The Baby Moves prospective cohort study protocol: using a smartphone application with the General Movements Assessment to predict neurodevelopmental outcomes at age 2 years for extremely preterm or extremely low birthweight infants*. *BMJ open*, 2016. **6**(10): p. e013446.
21. Adde, L., et al., *Early prediction of cerebral palsy by computer-based video analysis of general movements: a feasibility study*. *Developmental Medicine & Child Neurology*, 2010. **52**(8): p. 773-778.
22. Adde, L., et al., *Using computer-based video analysis in the study of fidgety movements*. *Early Human Development*, 2009. **85**(9): p. 541-547.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
23. Raghuram, K., et al., *Automated movement analysis to predict motor impairment in preterm infants: a retrospective study*. Journal of Perinatology, 2019.
24. Karch, D., et al., *Quantification of the segmental kinematics of spontaneous infant movements*. Journal of biomechanics, 2008. **41**(13): p. 2860-2867.
25. Philippi, H., et al., *Computer-based analysis of general movements reveals stereotypies predicting cerebral palsy*. Developmental Medicine & Child Neurology, 2014. **56**(10): p. 960-967.
26. Kanemaru, N., et al., *Specific characteristics of spontaneous movements in preterm infants at term age are associated with developmental delays at age 3 years*. Developmental Medicine & Child Neurology, 2013. **55**(8): p. 713-721.
27. Woolfenden, S., et al., *Developmental vulnerability – don't investigate without a model in mind*. Child: Care, Health and Development, 2015. **41**(3): p. 337-345.
28. Walker, S., et al., *Child Development 1: Inequality in early childhood: risk and protective factors for early child development*. The Lancet, 2011. **378**(9799): p. 1325-38.
29. Maggi, S., et al., *The social determinants of early child development: An overview*. 2010: Melbourne, Australia. p. 627-635.
30. Bronfenbrenner, U. and S.J. Ceci, *Nature–Nurture Reconceptualized in Developmental Perspective: A Bioecological Model*. Psychological Review, 1994. **101**(4): p. 568-586.
31. von Elm, E., et al., *The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies*. Annals of Internal Medicine, 2007. **147**(8): p. 573-577.
32. Cohen, J.F., et al., *STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration*. BMJ Open, 2016. **6**(11): p. e012799.
33. Hagemann, E., et al., *The ORIGINS project*, in *Pre-emptive medicine: Public health aspects of developmental origins of health and disease, Current topics in environmental health and preventive medicine*, Sata F, Fukuoka H, and H. M, Editors. 2019, Springer Nature: Singapore. p. 99 - 116.
34. The Australian Cerebral Palsy Register, G., et al., *Australian Cerebral Palsy Register Report 2016*. 2016, Unpublished.
35. Kwong, A., et al., *The Baby Moves smartphone app for General Movements Assessment: Engagement amongst extremely preterm and term-born infants in a state-wide geographical study*. Journal of Paediatrics and Child Health, 2018.
36. Ustad, I.T., et al., *Validity of the General Movement Optimality List in Infants Born Preterm*. Pediatric Physical Therapy, 2017. **29**(4): p. 315-320.
37. LeBreton, J.M. and J.L. Senter, *Answers to 20 Questions About Interrater Reliability and Interrater Agreement*. Organizational Research Methods, 2008. **11**(4): p. 815-852.
38. Morais, R., et al., *Learning regularity in skeletal trajectories for anomaly detection in videos*, in *Conference on Computer Vision and Pattern Recognition 2019: Long Beach, California*. p. 11996-12004.
39. Venkatesh, S., P. Vellank, and V. Le, *Accuracy of machine scoring of fidelity movements from high risk infant populations*. Cerebral Palsy Alliance: New South Wales.
40. Bayley, N. and G.P. Aylward, *Bayley Scales of Infant and Toddler Development*. 4th Ed. ed. 2019, San Antonio: Harcourt.

- 1
- 2
- 3
- 4 41. Anderson, P., et al., *Underestimation of developmental delay by the new*
- 5 *Bayley-III scale*. Archives of Pediatric and Adolescent Medicine, 2010. **164**(4):
- 6 p. 352 - 356.
- 7 42. Smaldone, A., A. Tsimicalis, and P. Stone, *Measuring resource utilization in*
- 8 *patient-oriented comparative effectiveness research: A psychometric study of*
- 9 *the Resource utilization questionnaire*. Research and Theory for Nursing
- 10 Practice: An international journal, 2011. **25**(2): p. 80-106.
- 11 43. Al-Janabi H, Flynn TN, and C. J, *Estimation of a preference-based carer*
- 12 *experience scale*. Medical Decision Making, 2011. **31**: p. 458 - 468.
- 13 44. Lavis, J.N., et al., *How can research organizations more effectively transfer*
- 14 *research knowledge to decision makers?* Milbank Q, 2003. **81**(2): p. 221-48,
- 15 171-2.
- 16 45. Ellen, M.E., et al., *Determining research knowledge infrastructure for*
- 17 *healthcare systems: a qualitative study*. Implementation Science, 2011. **6**(1):
- 18 p. 60.
- 19 46. Boote, J., R. Telford, and C. Cooper, *Consumer involvement in health*
- 20 *research: a review and research agenda*. Health Policy, 2002. **61**(2): p. 213-
- 21 36.
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



Study assessment timeline. GMA: General Movement Assessment. GMOS: General Movement Optimality Score. MOS: Motor Optimality Score. EI: Early Intervention

190x300mm (96 x 96 DPI)

BMJ Open

Early Moves: A protocol for a population-based prospective cohort study to establish General Movements as an early biomarker of cognitive impairment in infants.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041695.R1
Article Type:	Protocol
Date Submitted by the Author:	30-Sep-2020
Complete List of Authors:	<p>Elliott, Catherine ; Telethon Kids Institute; Curtin University, School of Occupational Therapy, Social Work and Speech Pathology Alexander, Caroline; Curtin University, School of Occupational Therapy, Social Work and Speech Pathology Salt, Alison; Perth Children's Hospital, Paediatric Rehabilitation Spittle, Alicia; The University of Melbourne Department of Physiotherapy, Physiotherapy; Murdoch Childrens Research Institute, Victorian Infant Brain Studies Boyd, Roslyn; The University of Queensland, Queensland Cerebral Palsy and Rehabilitation Research Centre; The University of Queensland, Queensland Children's Medical Research Institute Badawi, Nadia; Children's Hospital at Westmead, Neonatology Morgan, Catherine; The University of Sydney, Cerebral Palsy Alliance Silva, Desiree; The University of Western Australia Geelhoed, Elizabeth; The University of Western Australia, School of Population Health Ware, Robert; Griffith University, Menzies Health Institute Queensland Ali, Alishum; Curtin University McKenzie, Anne; The University of Western Australia Bloom, David; Harvard University T H Chan School of Public Health Sharp, Mary; The University of Western Australia, School of Paediatrics and Child Health Ward, Roslyn; Curtin University, School of Occupation Therapy, Social Work and Speech Pathology Bora, Samudragupta; Mater Research, Mothers, Babies and Women's Health Program Prescott, Susan; The University of Western Australia Woolfenden, Susan ; Local Government and Shires Association of NSW, ; University of New South Wales, Le, Vuong; Deakin University Davidson, Sue-Anne; Perth Children's Hospital, Paediatric Rehabilitation Thornton, Ashleigh; University of Western Australia, Finlay-Jones, Amy; Telethon Kids Institute; Curtin University, School of Psychology Jensen, Lynn; Curtin University Amery, Natasha; Curtin University, School of Occupational Therapy, Social Work and Speech Pathology Valentine, Jane; Perth Children's Hospital, Paediatric Rehabilitation; On behalf of the Early Moves Clinical Working Group</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Diagnostics, Rehabilitation medicine
Keywords:	Developmental neurology & neurodisability < PAEDIATRICS, Community child health < PAEDIATRICS, PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Early Moves: A protocol for a population-based prospective cohort study to**
4 **establish General Movements as an early biomarker of cognitive impairment in**
5 **infants.**
6
7

8
9 Lead author: Catherine Elliott, Curtin University
10

11 Co-authors:
12

13
14 Alexander, C; Curtin University

15 Salt, A; Perth Children's Hospital

16 Spittle, A; University of Melbourne

17
18 Boyd, RN; The University of Queensland

19
20 Badawi, N; CP Alliance Research Institute, Grace Centre for Newborn Intensive
21 Care, The Children's Hospital at Westmead, University of Sydney

22 Morgan, C; CP Alliance Research Institute, University of Sydney

23
24 Silva, D; University of Western Australia

25 Geelhoed, E; University of Western Australia

26
27 Ware, RS; Menzies Health Institute Queensland, Griffith University

28 Ali, A; Curtin University

29
30 McKenzie, A; University of Western Australia

31 Bloom, D; Harvard University

32
33 Sharp, M; University of Western Australia

34 Ward, R; University of Notre Dame

35
36 Bora, S; Mothers, Babies and Women's Health Program, Mater Research Institute,
37 Faculty of Medicine, The University of Queensland, Brisbane, Australia

38
39 Prescott, S; University of Western Australia

40
41 Woolfenden, S; University of New South Wales

42
43 Le, V; Deakin University

44
45 Davidson, S; Perth Children's Hospital

46
47 Thornton, A; Perth Children's Hospital, University of Western Australia

48
49 Finlay-Jones, A; Telethon Kids Institute

50
51 Jensen, L; Curtin University

52
53 Amery, T; Curtin University

54
55 Early Moves Clinical Working Group

56
57 Jane Valentine

58
59 Alison Salt
60

1
2
3 Desiree Silva
4 Caroline Alexander
5 Natasha Amery
6 Arlette Coenen
7 Rose Morie
8 Jennifer Moore
9 Madeleine OConnor
10 Ravisha Srinivasjois
11 Jason Tan
12 Brad Jongeling
13 Elayne Downie
14 Ruth Last
15 Mary Sharp
16 John Wray
17 Sue-Anne Davidson
18 Ashleigh Thornton
19
20
21
22

23 Valentine, J; Perth Children's Hospital
24
25

26 Corresponding author: Jane Valentine, Perth Childrens Hospital, 15 Hospital Av,
27 Nedlands 6009, WA. Jane.valentine@health.wa.gov.au
28
29

30
31
32 Word Count: 4,888 words
33

34 Number of Figures: 1
35

36 Number of Tables: 1
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract:

Introduction:

The current diagnostic pathways for cognitive impairment rarely identify babies at risk before 2 years of age. Very early detection and timely targeted intervention, has potential to improve outcomes for these children and support them to reach their full life potential. *Early Moves* aims to identify early biomarkers, including General Movements (GMs), for babies at risk of cognitive impairment, allowing early intervention within critical developmental windows to enable these children to have the best possible start to life.

Method and analysis:

Early Moves is a double masked prospective cohort study that will recruit 3,000 term and preterm babies from a secondary care setting. *Early Moves* will determine the diagnostic value of abnormal GMs (at writhing and fidgety age) for mild, moderate and severe cognitive delay at two-years measured by the Bayley-4. Parents will use the Baby Moves smart-phone app to video their babies' GMs. Trained GMs assessors will be masked to any risk factors and assessors of the primary outcome will be masked to the GMs result. Automated scoring of GMs will be developed through applying machine-based learning to the data and the predictive value for an abnormal GM will be investigated. Screening algorithms for identification of children at risk of cognitive impairment, using the GM Assessment (GMA), and routinely collected social and environmental profile data will be developed to allow more accurate prediction of cognitive outcome at 2 years. A cost evaluation for GMA implementation in preparation for national implementation will be undertaken including exploring the relationship between cognitive status and health care utilisation, medical costs, health-related quality of life and caregiver burden.

Ethics and dissemination:

Ethics approval has been granted by the Medical Research Ethics Committee of Joondalup Health Services and the Health Service Human Research Ethics Committee (1902) of Curtin University (HRE2019-0739).

Trial registration number: ACTRN12619001422112

Article Summary

Strengths and limitations of this study:

- This is the first population based prospective cohort study investigating the utility of the General Movements assessment as a biomarker to identify children with cognitive impairment during early infancy.
- This is the first study to explore the feasibility of using smart phone app based video collection of writhing and fidgety GMs in a large representative population.
- This study will develop automated scoring of the GMs using machine learning making wide scale screening possible in the future.
- This study will combine the GMA outcome, with routinely collected demographic and health data to develop a screening algorithm for identification of infants at risk of cognitive impairment.

Key Words (MeSH Terms):

- Cognitive Dysfunction
- Infant
- Child Development
- Cohort Studies
- Neonatal Screening

Introduction

Neurodevelopmental disorders (NDD) result from changes in the brain that lead to an impairment in skill development, including cognitive, language and motor skills [1]. The lifelong impact of NDD has enormous personal and financial burden on the individual, their family and the community. Nationally in Australia, the cost of intellectual disability alone, is estimated to be \$14,720 billion annually [2]. In Western Australian (WA), 6.6% of children meet the criteria for 'developmentally vulnerable' at school entry with regard to language and cognition [3], while the prevalence of diagnosed intellectual disability in WA children is 14.3/1000 [4].

The first two years of life are a critical period for motor and cognitive development due to the timing of corticospinal tract development and the plasticity mechanisms at work in the infant's brain [5]. Thus, the earlier cognitive impairment can be detected, the greater the potential benefits of ensuing early interventions for optimising neuroplasticity, preventing or ameliorating neurodevelopmental disorders and enhancing parental wellbeing. Early interventions for cognitive development have been explored in preterm and low birth weight infants. Though systematic review of the topic suggests benefits may be restricted to short-term gains [6, 7], comprehensive long term follow up analysis indicates some biological risk factors significantly affect response to the intervention [8]. For example, higher-low birth weight infants stood to gain the more from early intervention with cognitive improvements seen up at 18 years of age compared to lower-low birth weight infants [8, 9].

It remains difficult to accurately identify infants at risk of cognitive impairment [10-13] in the absence of other risk factors such as prematurity or low birth weight, making it impossible to assess interventions for children in the general population at risk of cognitive delay. This lack of identification pathways is highlighted by the considerable delay that is often reported between parents' first concerns and confirmation of a diagnosis [14]. This is more pronounced for those residing outside major centres, with a known health inequality in regional and rural Australia, and in poorly served outer metropolitan areas of large cities [15].

General Movements (GMs) are a distinct spontaneous movement pattern evident in babies before and after birth [16]. Writhing GMs are movement sequences of

1
2
3 variable speed, amplitude and intensity which are observed in utero up to 8 weeks
4 post-partum, with the most significant abnormality involving sudden and
5 synchronised cramping of the trunk and limbs [17]. Fidgety GMs are small twitches
6 at the joints such as fingers, ankle and neck, which are present from 8 to 20 weeks'
7 post-term. The absence of these small twitches is the most notable abnormality seen
8 at this age [18, 19]. General Movements are now recognised as a sensitive tool for
9 providing information on the integrity of a baby's brain function [20, 21]. The absence
10 of fidgety GMs is the best predictor of cerebral palsy in high-risk infants, with pooled
11 estimates of 98% sensitivity and 91% specificity [21].

12
13 While the GMs are accurate for predicting motor impairment, recent evidence
14 suggests GMs may be a biomarker for identifying cognitive impairment in preterm
15 infants [22, 23]. In two systematic reviews higher risk of cognitive impairment was
16 associated with persistence of abnormal writhing GMs until 8 weeks after term and
17 with monotonous movement sequences and postural abnormalities at 12-20 weeks.
18 Further, the developmental quotient at 2-3 years of children born preterm, with
19 abnormal writhing GMs at 4 weeks post-term, was lower than gestation and age
20 matched infants with normal writhing GMs [23].

21
22 Abnormal fidgety GMs in preterm infants was also found to be associated with a
23 score on average eight points lower on the Bayley Scales of Infant and Toddler
24 Development—Second Edition at two years of age compared to those with normal
25 fidgety GMs [24]. This difference in cognition was greater when the children were
26 reassessed at age four years on the Differential Ability Scale [24]. These findings
27 indicate that abnormal spontaneous movement patterns, at both the writhing and
28 fidgety stages, may presage later cognitive impairment. The majority of this
29 evidence however exists in preterm and high-risk infants; there is a paucity of
30 information for healthy term infants.

31
32 More detailed scoring of the GM, in which every movement criterion are given a
33 score [25] is known as the GM Optimality Score (GMOS) at the writhing age [17],
34 and the Motor Optimality Score (MOS) at the fidgety age [26], where a higher score
35 represents more optimal movements. Full explanation of movement criteria is
36 available in previous publications by the GM trust [17, 25] . In a study of 40
37 extremely preterm infants, 33 infants showed normal fidgety movements, but of
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 these 33 infants only six were found to have the highest MOS score possible [27],
4 highlighting the increased sensitivity of optimality scoring compared to global GMA.
5
6

7 Should GMs be shown to be an early biomarker for cognitive impairment, there are
8 still barriers to implementing GMA as a population level screening tool. These
9 barriers include access to trained assessors in many locations, and the cost involved
10 in video recording of the infant. To overcome these barriers, a smart-phone app
11 called Baby Moves has been developed allowing families or health professionals to
12 record and upload GM recordings directly and has been successfully utilised for
13 fidgety age assessments on high risk infants [28], removing the need for in-person
14 appointments.
15
16

17 The use of machine based movement recognition, aimed at automatic detection,
18 classification and quality assessments of limb movements has the potential to further
19 reduce the time and financial costs of GM assessments. This approach has been
20 explored by a number of researchers aiming to automate reporting of fidgety GMs in
21 small samples of clinical GM videos [29-34]. Results suggest automated readings of
22 fidgety movements are feasible, reporting sensitivity and specificity of 79-85% and
23 63-71% respectively [29-31]. The machine learning field is relatively young, and is
24 rapidly evolving and advancing. Through adoption of new techniques, and a large
25 training dataset, it is expected the sensitivity and specificity can be improved [35].
26 Automated video analysis may provide a low-cost, high sensitivity approach by
27 combining the sensitivity of advanced machine classification (used as a primary
28 screening mechanism), and the specificity of human expert opinion (for any videos
29 classified as high risk by the automation).
30
31

32 It is known that a child's biological and environmental profile is related to
33 developmental outcomes [36-38]. A number of protective and risk factors, particularly
34 birth weight, gender and prematurity, and maternal age are routinely collected and
35 documented. Applying a bioecological model [39] to explore developmental
36 vulnerability using routinely collected data, in conjunction with GM assessments may
37 provide a stronger predictive tool than GM's alone creating a robust and meaningful
38 screening tool [36].
39
40

41 Identification of an early biomarker, along with the development and validation of an
42 accessible affordable and scalable screening tool, for the early identification of
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 cognitive impairment would allow a greater number of infants to receive effective
4 early interventions during the critical window of brain development: an advantage to
5 the child, family and greater society.
6
7

8
9 *“The economic benefit [of early detection and intervention] could be great, but the*
10 *benefit to the families is priceless”*
11

12
13 *-Kids Rehab WA Consumer group member*
14

15 **Aims and Hypothesis**

16 Phase One – GMA as a biomarker

17
18 The primary aim of phase one is to determine the diagnostic value of GMs for
19 cognitive delay at two-years.
20
21

22 It is hypothesised that abnormal GMs at either writhing or fidgety age will be
23 predictive of cognitive delay at two years. As this is the first study to look at the
24 predictive ability of GMA for cognitive delay or impairment in a large representative
25 birth cohort, we have insufficient data to hypothesise the diagnostic test accuracy.
26
27

28 The secondary aim of phase one is to develop and refine automated assessment for
29 both writhing and fidgety periods respectively, including optimality scoring, through
30 applying machine based learning to the data. It is hypothesised that automated
31 scoring of GMA will have >90% sensitivity and >85% specificity to detect global GM
32 abnormalities, with lower accuracy for optimality scores.
33
34

35 Phase Two – Screening algorithm

36 The primary aim of phase two is to develop screening algorithms for identification of
37 children at risk of cognitive impairment, using the GMA, and routinely collected social
38 and environmental profile data.
39
40

41 It is hypothesised an algorithm of early child, family and societal risk factors and
42 GMA and optimality scores, will be a more accurate predictor of cognitive status at 2
43 years corrected age than GMA or optimality scores alone.
44
45

46 Phase Three – Cost and economic evaluations

1
2
3 The primary aim of phase three is to conduct a cost evaluation for GMA
4 implementation from the perspective of the funder in preparation for national
5 implementation.
6
7

8
9 The secondary aim of phase three is to assess the relationship between cognitive
10 status and health care utilisation, medical costs, health-related quality of life and
11 caregiver burden.
12
13

14
15 It is hypothesised cognitive impairment will predict; higher health care utilisation and
16 direct medical costs, poorer health-related quality of life and higher caregiver burden.
17
18

19 **Methods**

20 **Study Design**

21
22 This study is a double-masked, prospective cohort study of 3,000 babies. The
23 methodological design of this cohort study has been informed by the 2007
24 “Strengthening the Reporting of Observational Studies in Epidemiology” (STROBE)
25 checklist for cohort studies [40]. The methodological design of phase one (a study of
26 diagnostic test accuracy), was informed by the 2015 “Standard for Reporting of
27 Diagnostic Accuracy Studies” (STARD) checklist [41].
28
29
30
31
32
33

34 **Setting**

35
36 Early Moves is a multi-site study, recruiting in secondary care settings in
37 metropolitan Perth, WA. This study is a sub-study of the ORIGINS project, a major
38 Western Australian cohort study of 10,000 families who birth at Joondalup Health
39 Campus, WA, a public/private secondary hospital in Perth’s northern suburbs [42,
40 43]. The ORIGINS project is the largest representative sample of Australian infants
41 in an observational cohort study, and includes a number of optional nested
42 interventional studies. Early Moves will initiate recruitment through the ORIGINS
43 project, before expanding to additional metropolitan secondary hospitals.
44
45
46
47
48
49
50

51 **Recruitment**

52
53 *Early Moves* will recruit a total of 3,000 infants between November 2019 and
54 December 2022. It is anticipated two thirds of participants will be recruited through
55 the ORIGINS project. Recruitment can occur at any time, from initial presentation at
56 antenatal clinic, up until discharge from hospital after the birth of the baby. To reduce
57
58
59
60

1
2
3 risk of self-selection bias on the basis of birth experience, antenatal recruitment will
4 be targeted where possible (Figure 1). Timing of consent relative to birth will be
5 recorded. Potential participants will be recruited directly by their maternity or
6 postnatal care provider, or by a member of the ORIGINS or Early Moves research
7 team. Recruitment flyers and posters will also be used at study sites. The first 3000
8 eligible participants who provide informed consent will be enrolled in Early Moves. As
9 all mothers birthing at each site are invited to participate in the study we anticipate
10 the rates of preterm to be similar to that found in the general population at 8.2% [44].
11
12
13
14
15
16
17

18 *Inclusion Criteria*

- 19
20 a) Mother intending on birthing/have recently birthed at a select WA public or
21 private hospital between 2019 and 2023
22
23

24 *Exclusion Criteria*

- 25
26 a) Babies enrolled in an ORIGINS interventional research study that aims to
27 promote cognitive and language development.
28
29
30

31 *Masking*

32
33 The assessors will be masked to baby's gestation at birth; birth, medical and social
34 history and the results of any of the ORIGINS or *Early Moves* outcomes.
35 Abnormalities in serial GM assessments are known to be predictive of cerebral
36 palsy, so in cases where abnormalities are identified, the participants will be notified
37 and referred to the appropriate clinical services for further investigation and
38 management. Based on rate of cerebral palsy in Australia of 1.4 per 1000 live births
39 [45], we anticipate to identify approximately 5 cases of cerebral palsy, where parents
40 will be unmasked to GM outcomes as per above protocol.
41
42
43
44
45
46
47

48 *Bias*

49
50 As a prospective cohort study selection bias is minimised as participants will enrol
51 prior to or very soon after the birth of the baby. Inhomogeneity of the cohort and
52 exposure to other interventions (interventions that do not meet the exclusion criteria)
53 will be explored as potential biases. , Where available, Ages and Stages
54 Questionnaire [42] (administered as part of the ORIGINS project), will be used to
55 explore study bias for drop out in the *Early Moves* study. Exclusion from *Early Moves*
56
57
58
59
60

1
2
3 on the basis of enrolment in an intervention study will be reviewed to explore
4 selection bias relating to risk of neurodevelopmental disorder.
5
6

7 Phase One: Predictive Variables 8

9
10 General Movements will be obtained using the Baby Moves smartphone app. A 3
11 minute video is taken using the app with the baby lying supine on a plain, flat surface
12 in an awake, settled state, with arms and legs visible. Videos are securely uploaded
13 to the study database for remote assessment by the GM assessors according to
14 Prechtl's GMA, and calculation of GMOS [17, 25] and MOS [25, 26]. The Baby
15 Moves app has been successfully piloted on 446 infants to determine feasibility at
16 the fidgety period [28, 46], with 69.9% - 82.7% of the videos taken by families
17 scorable [46]. This study seeks to reduce the proportion of un-scorable videos to
18 15% by employing personalised training and parental education, instructional films
19 and the use of e-reminders of upcoming and currently due videos, and phone
20 support. Further, as this study commences with the first video made within 2 weeks
21 post-term rather than 12 weeks post-term, we anticipate families will be more
22 engaged with the study compared with early studies using the Baby Moves app.
23 Videos received will be reviewed within two weeks of submission to check for quality,
24 and families will be contacted via phone if the video is un-scorable. Collection of two
25 videos within each time period further increases the likelihood of one scorable video
26 being attained within each time period.
27
28
29
30
31
32
33
34
35
36
37
38

39 Remote GMA will be conducted for each of the two time periods, (Figure 1). For the
40 purpose of exploring the predictive ability of GM on cognitive impairment,
41 assessment will be conducted on the first video, with the second video used if a) the
42 first is not scorable, or b) there is uncertainty around classification and further video
43 footage is required to make a final decision.
44
45
46
47

- 48 1. Time-period 1 "Writhing" – videos collected at 1+0 to 2+6 and 3+0 to 4+6
49 weeks post-term age. Movements will be classified, and GMOS calculated.
50
- 51 2. Time-period 2 "Fidgety" – videos collected at 12+0 to 13+6 and 14+0 to 16
52 +6 weeks post-term age. Movements will be classified and MOS calculated.
53
54
55

56 *General Movement Fidelity* 57 58 59 60

1
2
3 General Movement Assessments will be conducted by qualified and registered
4 clinicians who have experience in reporting GMA's and have passed the advanced
5 GMs course by the General Movements Trust. The assessors must have experience
6 in clinical and research application of GM assessment prior to involvement in the
7 study.
8
9

10
11
12 Each GM and GMOS/MOS assessment will be conducted by two individual
13 assessors. If there is disagreement between the two assessors a third blinded,
14 experienced GM Instructor (ASp or CM), will make the final decision. Disagreement
15 is defined as difference in GM categorical assessment, or optimality scores of more
16 than five point difference [47].
17
18
19

20
21
22 The interrater reliability of the three assessors for GMA will be accepted as “almost
23 perfect” ($\geq 82\%$ of data are reliable, with Cohen's Kappa > 0.9). Interrater reliability
24 and agreement for GMOS and MOS will be accepted as “excellent reliability”
25 (intraclass correlation coefficient of > 0.9 using two-way random effects ANOVA) [48].
26 This will be done by triple scoring the first 10 videos, then 10% (selected at random)
27 of each block of 100 videos until criteria for reliability are met. To ensure reliability is
28 maintained throughout the study, a random selection of 10 videos out of every 300
29 will be triple scored.
30
31
32
33
34
35

36 *Automated reading of GMA*

37

38
39 Advanced machine learning methods have been developed to classify and separate
40 normal versus abnormal videotaped fidgety GM [46, 49]. Video recordings are
41 processed using a pipeline of computer vision and machine learning techniques to
42 predict GMA. Salient point detection (where the joints related to the GM of the infant
43 are located and tracked in the video frames) is followed by extraction of the local
44 motions of the joints into feature vectors. These feature vectors are automatically
45 classified using our anomaly detection algorithm developed during pilot work [49,
46 50]. Based on a k – nearest neighbour classification approach on 265 video
47 recordings of babies, and a feature based on the histogram of the optical flow, the
48 accuracy for automated GMA is 72.9% [50].
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Source of routinely collected demographic and health factors used for the development of screening algorithms in Phase Two. Factors are grouped according to levels, employing a bioecological model of child development. JHC: Joondalup Health Campus

	Midwives Notification System	JHC Mother's Health Questionnaire
Cultural and Neighbourhood Factors		
Socioeconomic Index (SEIFA)	√	
Ethnicity	√	
Parent/Family Factors		
Marital status	√	√
Smoking during pregnancy	√	√
Alcohol consumption during pregnancy	√	√
Illicit drug use during pregnancy		√
Maternal Medical Conditions	√	
Maternal Mental Health Conditions		√
Perinatal Mental Health Risk Factors	√	
Child/Biological Factors		
Pregnancy complications	√	√
Family History of Developmental Difficulties		√
Method of Birth	√	
Complications of labour and birth	√	
Gender	√	
Infant Weight	√	
Resuscitation	√	
Estimated Gestation	√	
Birth defects	√	
Birth trauma	√	
Special care number of days	√	
Plurality	√	

Phase One: Primary Outcomes

The *Bayley Scales of Infant and Toddler Development* is the most frequently used test in infant developmental assessments [51]. The fourth edition of the scale

(Bayley-4) has recently been released and will be used in this study at age 2 years corrected. The Bayley-4 scores across five subdomains: Cognitive, Language, Motor, Social-Emotional and Adaptive Behaviour. In *Early Moves* the primary outcome will compute a combined cognitive *and* language score calculated as the average of the cognitive score and the language score [52, 53]. Cognitive delay will be defined as severe when cognitive *and* language score is greater than 3 standard deviations (SD) below the Australian mean, moderate when the score is between 2 and 3SD below the Australian mean, and mild when the score is between 1 and 2SD below the Australian mean [54]. Children unable to complete psychological testing because of presumed severe cognitive delay will be assigned a score of -4 SD. Secondary analysis will be conducted on cognitive domain score alone. If babies score <-2SD on the Bayley-4 across any domain, they will be referred to the appropriate developmental services for further investigation and management.

Medicare Benefit Scheme data and health resource use questionnaires will be used to identify participants who have received cognitive interventions as part of their standard clinical care and a sensitivity analysis will be performed to assess the extent to which inclusion of these participants identified as high risk of cognitive impairment impacts the primary results.

Phase Two: Screening Algorithms

Screening algorithms for identifying children requiring early intervention for cognitive delay will be developed using data available from the Joondalup Health Campus (JHC) Mothers Health Questionnaire (routinely administered to all mothers intending to birth a JHC), and the Midwives Notification System (Table 1). Linked data from the Western Australian Register of Developmental Anomalies at age 1 year will be utilised.

Phase Three: Health Economics

Health care resources will be measured and standard cost sources will be used to apply unit costs to resources. Costs will be standardised to a reference year and future costs will be discounted according to standard practice. Resources and associated costs will include GMA and Bayley-4. The cost of GMA will include ongoing cost of the app and labour resources required for assessment of the videos. Data collected on health-related resource use will include screening assessments,

1
2
3 therapy frequency and duration (traditional/alternate), hospital admissions, GP and
4 medical specialist visits, medications and equipment.. Data will be collected via the
5 Health Resource use (HRU) questionnaire [55], supplemented by consented access
6 to individual hospital, Medical Benefits Scheme (MBS) and Pharmaceutical Benefits
7 Scheme (PBS) records.
8
9

10
11
12 The *Carer Experience Scale (CES)* will be employed as a measure of caregiver
13 burden. This validated measure of care-related quality of life has six domains
14 (activities, support, assistance, fulfilment, control and relationship with the care
15 recipient) and takes approximately 3 minutes to complete [56]. The Carer Experience
16 Scale is scored from an algorithm derived from preferences of the general population
17 and can be used to value carer outcomes in economic evaluation using index values
18 [56].
19
20
21
22
23
24

25 Sample Size Estimation

26
27
28 *Early Moves* is a double masked prospective cohort study and will recruit 3,000
29 babies. For the primary aim to determine the diagnostic value of abnormal GMs for
30 cognitive delay at two-years, this sample size will be sufficient to establish >78%
31 sensitivity and >83% specificity (alpha 0.05) This calculation assumes 15% of
32 participants have at least mild cognitive delay, the actual sensitivity and specificity
33 are 82.5% and 85% respectively, that 15% of participants drop out at 2-year follow
34 up and that 15% of videos are not scorable. For secondary outcomes, there is
35 sufficiently high power to detect even small associations between early GM results
36 and Bayley-4 interval scores at 2years. For example if 80% of children have normal
37 GMs as infants, the study is powered to detect between group (GM normal vs
38 abnormal) differences on the Bayley- 4 (cognitive and language) at 2 years of 3.5
39 points or greater with 80% power (assuming alpha=0.05, and SD=15 points).
40
41
42
43
44
45
46
47
48

49 Statistical Analysis

50
51 Summary statistics will be described using either mean (standard deviation) or
52 median (25th-75th percentile) for continuous variables, according to distribution, or
53 as frequency (percentage) for categorical variables.
54
55
56

57 For Phase One, the primary aim will be assessed using standard diagnostic statistics
58 (e.g. sensitivity, specificity, predictive values, and likelihood ratios). The predictive
59
60

1
2
3 validity of the GM categorical classification will be established using logistic
4 regression. The diagnostic value of machine learning for identifying GM writhing and
5 fidgety categorical classification will be evaluated by determining the accuracy,
6 precision, recall and area under the curve (AUC) of both automated machine
7 assessment and machine-human hybrid assessment using the entire dataset of
8 videos (n=6000). An algorithm for early diagnosis of cognitive impairment will be
9 developed using logistic regression modelling, using variables from the GMOS/MOS,
10 GMA categorical classification. Variables will be entered using forward selection
11 based on the Wald statistic. Sensitivity and specificity of the regression model, with
12 95% confidence intervals will be established.

13
14 For Phase Two, screening algorithms based on the association between
15 measurements recorded at birth or in infancy (e.g. GM category) and measurements
16 recorded at 2 years will be assessed using linear regression for interval outcome
17 data, logistic regression for binary outcome data, and Poisson regression for count
18 outcome data. Hierarchical mixed-effects models will be used with 'participant'
19 included in the model as a random effect in order to account for the non-
20 independence of observations from the same participant. Motor impairment and
21 known risk factors (prematurity, low birth weight, diagnosis of other developmental or
22 genetic disorder) will be tested as a potentially confounding variable for all models.
23 Variables will be selected for potential inclusion in multivariable models based on
24 univariable significance at the $p < 0.2$ level. Multivariable models will be built in a step-
25 wise manner with redundant variables eliminated using Akaike's and Schwarz's
26 Bayesian criteria. Interactions will be investigated as appropriate.

27
28 For Phase Three, cost and economic evaluations will consider service use and
29 service costs. We will describe patterns of met and unmet need in the study children,
30 and indirect costs to families will be examined. Associations between costs and all
31 other outcome variables, including those related to cognitive outcome will be
32 assessed, with adjustment for confounders.

33 Ethics and dissemination

34
35 The ORIGINS Project (ref. #1440) and *Early Moves* (ref. #1902) has been approved
36 by the Human Research Ethics Committee of JHC. Participant information booklets
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 will be provided to all participants prior to entry into the study, and full written and
4 informed consent will be obtained from all participants.
5
6

7 A collaborative (push, pull, exchange) knowledge translation model has been
8 adopted in this study [57, 58]. Project investigators will champion knowledge
9 translation across five levels of Health: Consumer and Service Providers;
10 Department; Program; and Health Service Level. Specific knowledge translation
11 strategies and skill building activities will be targeted across the phases of the *Early*
12 *Moves* Project, and in consultation with our stakeholders. This will include, but are
13 not limited to, dissemination of findings to consumers and stakeholders via peer
14 reviewed publication of study results, plain language summaries, newsletter
15 feedback and media case studies, as well as presentations at key national and
16 international conferences.
17
18
19
20
21
22
23
24

25 Public/patient involvement

26
27 Community engagement is at the core of the ORIGINS and *Early Moves* projects
28 [42], with the implementation of a collaborative model of involvement [59].
29 Community members of a clinical consumer reference group were involved in the
30 priority setting for the study, specifically parents of children with cognitive
31 impairment. When asked whether they felt the study was important and worthwhile,
32 the response was very positive, e.g. "Yes, yes, yes. I don't understand why you
33 wouldn't do it." The group also endorsed time points, methods for collection of data
34 and follow up protocols for abnormal GMA results. Furthermore, ORIGINS has a
35 dedicated community stakeholder coordinator and 12 parents whom form a
36 consumer reference group. This ORIGINS consumer reference group has been
37 involved in development of recruitment and information and consent materials for
38 *Early Moves*. Consumer and community representation is also incorporated in the
39 ORIGINS and *Early Moves* governance structure.
40
41
42
43
44
45
46
47
48
49

50 Bidirectional, effective and continuous communication with consumers will guide
51 research directions, interpretation of findings and their implications for policy.
52
53

54 **Discussion**

55
56
57 At present, lack of early biomarkers for cognitive impairment hinders referral to early
58 interventions. *Early Moves* aims to identify early biomarkers for babies at risk of
59
60

1
2
3 cognitive impairment, allowing early intervention within critical developmental
4 windows to enable babies to have the best possible start to life.
5
6

7 The study has a number of strengths. It is a well powered study with a population-
8 based sample. Where possible, participants will be recruited during the antenatal
9 period to minimise self-selection bias where it relates to the birth experience (e.g.
10 prematurity; late pregnancy or birth complications). The assessment variables
11 utilised in this study have proven reliability and validity. As a sub-project of the
12 ORIGINS project, *Early Moves* will have access to biobank data, to generate a
13 detailed biological and environmental risk profile, to inform predictive algorithms, and
14 investigate links between cognitive impairment and biological and environmental
15 factors. The study has strong consumer involvement and an embedded knowledge
16 translation plan which will help guide and facilitate the translation of research
17 findings in to clinical practice.
18
19
20
21
22
23
24
25

26 A potential limitation is that the final outcome measure is conducted at two years.
27 Research in premature babies shows the association between abnormal GMs and
28 cognitive impairment is weaker at 2 years compared to 4 years [24]. A subset of the
29 cohort will however be followed until age 5 years as part of the ORIGINS project,
30 with later assessments to include developmental assessments such as Ages and
31 Stages questionnaires and linkage to the Australian Early Development Census
32 (AEDC) providing data on early childhood development at entry to the first year of full
33 time school. The AEDC is an Australian wide data collection conducted by teachers
34 using the Australian version of the Early Development Instrument. . This study is also
35 potentially limited by recruitment at greater metropolitan sites within one Australian
36 city. Demographic data will be available to aid in the interpretation of generalisability
37 to other populations.
38
39
40
41
42
43
44
45
46

47 *Early Moves* will provide novel care models in rural and remote communities through
48 the use of smart phone technology and machine based learning, facilitating the
49 feasibility of app-based GM assessments as a population wide assessment tool.
50 Through combining automated app-based GM assessments with routinely collected
51 risk and protective factors, employing a bioecological model of development, *Early*
52 *Moves* recognizes the complex interplays of risk and protective factors to create a
53 robust screening tool for cognitive impairment in infants. Inclusion of health
54
55
56
57
58
59
60

1
2
3 economics evaluation will further enhance the potential for this technology to be
4 translated in to clinical care.
5

6 7 Acknowledgement

8
9 The authors would like to thank Svetha Venkatesh from Deakin University for her
10 contribution to this study, and The ORIGINS Project Team, including, but not limited
11 to Erika Haggeman, Jackie Davis, and Lucy Giggs for their contribution and support.
12
13
14

15 16 Conflict of Interest

17
18 None declared.
19

20 21 Funding

22
23 Supported by a Clinical Trials and Cohort Study Grant awarded by the National
24 Health and Medical Research Council, a Project Grant awarded by the Research
25 Foundation, Cerebral Palsy Alliance, a Project Grant awarded by the WA Child
26 Research Foundation, and a Project Grant awarded by the Perth Children's Hospital
27 Foundation.
28
29
30

31 32 Author Contributions

33
34 CE and JV are the chief investigators and together with CA, ASa, ASp, RNB, NB,
35 CM, DS, EG, and RSW designed established and achieved funding for the research
36 study. AA, AM, DB, MS, RW, SB, SP, SW, VL, SD, AT, LJ, NA, and the Early Moves
37 Clinical Working Party also contributed to study design. CE, JV and CA are
38 responsible for ethics applications and reporting. CA, DS, and SP are responsible for
39 recruitment. CE, JV, CA, ASa supervise the data collection and implementation of
40 training. CE, JV, ASa, AS, CM, MS, NA and the Early Moves Clinical Working Party
41 are responsible for design and implementation of GM outcomes. NB, CM and VL are
42 responsible for design and implementation of machine learning outcomes. AT, AM,
43 RW, SD and AA are responsible for design and implementation of consumer
44 engagement outcomes. EG and AFJ are responsible for design and implementation
45 of health economics outcomes. SW, DS and CA are responsible for design and
46 implementation of routinely collected screening outcomes. JV, ASa, and SB are
47 responsible for design and implementation of developmental outcomes. CE, JV, CA,
48 ASa, ASp, RNB, NB, CM, DS, EG, and RSW will take lead roles in preparation for
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 publications on the clinical outcomes of the study. RSW will take on a lead role of
4 statistical analysis for the study. All authors contributed to the preparation of this
5 manuscript and have approved the final version.
6
7

8 9 Data statement

10
11 De-identified individual participant data that underlie the results published in articles
12 resulting from this study will be made available to researchers on a case by case
13 basis, beginning 6 months and ending 5 years following the relevant article
14 publication. Data will be made available to researchers who provide a
15 methodologically sound proposal with appropriate research governance and ethics
16 approvals, for the purposes of achieving aims of approved proposal of for use in
17 meta-analysis. Proposals should be directed to Catherine Elliott OICR ID:
18
19
20
21
22
23 <https://orcid.org/0000-0002-5324-8216>
24

25
26 Figure 1: Study assessment timeline
27


28 29 References

- 30
31 1. Association, A.P., *Neurodevelopmental Disorders: DSM-5® Selections*. 2015:
32 American Psychiatric Pub.
- 33 2. Doran, C., et al., *How much does intellectual disability really cost? First*
34 *estimates for Australia*. J Intellect Dev Disabil., 2012. **37**(1): p. 42-49.
- 35 3. Commonwealth of Australia, *Australian Early Development Census National*
36 *Report 2018*. 2019: Canberra ACT.
- 37 4. Leonard, H., et al., *Prevalence of intellectual disability in Western Australia*.
38 Paediatric and Perinatal Epidemiology, 2003. **17**(1): p. 58-67.
- 39 5. Williams, P. and J. Martin, *Motor cortex activity organizes the developing*
40 *rubrospinal system*. Journal of Neuroscience, 2015. **35**(39): p. 13363-13374.
- 41 6. Orton, J., et al., *Do early intervention programmes improve cognitive and*
42 *motor outcomes for preterm infants after discharge? A systematic review*.
43 *Developmental Medicine & Child Neurology*, 2009. **51**(11): p. 851-859.
- 44 7. Spittle, A., et al., *Early developmental intervention programmes provided post*
45 *hospital discharge to prevent motor and cognitive impairment in preterm*
46 *infants*. Cochrane Database of Systematic Reviews, 2015(11).
- 47 8. Brooks-Gunn, J., et al., *Enhancing the Cognitive Outcomes of Low Birth*
48 *Weight, Premature Infants: For Whom Is the Intervention Most Effective?*
49 *Pediatrics*, 1992. **89**(6): p. 1209-1215.
- 50 9. McCormick, M.C., et al., *Early intervention in low birth weight premature*
51 *infants: results at 18 years of age for the Infant Health and Development*
52 *Program*. Pediatrics, 2006. **117**(3): p. 771-780.
- 53 10. Peyton, C., M.D. Schreiber, and M.E. Msall, *The Test of Infant Motor*
54 *Performance at 3 months predicts language, cognitive, and motor outcomes*
55 *in infants born preterm at 2 years of age*. Dev Med Child Neurol, 2018. **60**(12):
56 p. 1239-1243.
57
58
59
60

11. Morgan, C., *Towards more accurate prognostication after preterm birth*. *Developmental Medicine & Child Neurology*, 2018. **60**(12).
12. Wong, H.S., et al., *Developmental assessments in preterm children: A meta-analysis*. *Pediatrics*, 2016. **138**(2).
13. van't Hooft, J., et al., *Predicting developmental outcomes in premature infants by term equivalent MRI: systematic review and meta-analysis*. *Systematic Reviews*, 2015. **4**(1).
14. Scherzer, A., et al., *Global perspective on early diagnosis and intervention for children with developmental delays and disabilities*. *Dev Med Child Neurol.*, 2012. **54**(12): p. 1079-1084.
15. Australian Institute of Health and Welfare, *A picture of Australia's children 2012*, AIHW, Editor. 2012, AIHW: Canberra.
16. Prechtl, H.F., et al., *An early marker for neurological deficits after perinatal brain lesions*. *The Lancet*, 1997. **349**(9062): p. 1361-1363.
17. Einspieler, C., et al., *The general movement optimality score: a detailed assessment of general movements during preterm and term age*. *Developmental Medicine & Child Neurology*, 2016. **58**(4): p. 361-368.
18. Ferrari, F., et al., *Prechtl's method on the qualitative assessment of general movements in preterm, term and young infants*. 2004: Mac Keith Press.
19. Ferrari, F., et al., *The ontogeny of fidgety movements from 4 to 20 weeks post-term age in healthy full-term infants*. *Early Human Development*, 2016. **103**: p. 219-224.
20. Burger, M. and Q.A. Louw, *The predictive validity of general movements – A systematic review*. *European Journal of Paediatric Neurology*, 2009. **13**(5): p. 408-420.
21. Bosanquet, M., et al., *A systematic review of tests to predict cerebral palsy in young children*. *Developmental Medicine & Child Neurology*, 2013. **55**(5): p. 418-426.
22. Peyton, C. and C. Einspieler, *General Movements: A Behavioral Biomarker of Later Motor and Cognitive Dysfunction in NICU Graduates*. *Pediatric annals*, 2018. **47**(4): p. e159-e164.
23. Einspieler, C., et al., *The General Movement Assessment helps us to identify preterm infants at risk for cognitive dysfunction*. *Frontiers in Psychology*, 2016. **7**(406).
24. Spittle, A.J., et al., *General movements in very preterm children and neurodevelopment at 2 and 4 years*. *Pediatrics*, 2013: p. peds. 2013-0177.
25. Einspieler, C., et al., *Prechtl's method on the qualitative assessment of general movements in preterm, term and young infants*. *Clinics in Developmental Medicine*. Vol. 167. 2004: Mac Keith Press.
26. Einspieler, C., et al., *Cerebral palsy: Early markers of clinical phenotype and functional outcome*. *Journal of Clinical Medicine*, 2019. **8**.
27. Sharp, M., A. Coenen, and N. Amery, *General movement assessment and motor optimality score in extremely preterm infants*. *Early human development*, 2018. **124**(1): p. 38 - 41.
28. Spittle, A., et al., *The Baby Moves prospective cohort study protocol: using a smartphone application with the General Movements Assessment to predict neurodevelopmental outcomes at age 2 years for extremely preterm or extremely low birthweight infants*. *BMJ open*, 2016. **6**(10): p. e013446.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
29. Adde, L., et al., *Early prediction of cerebral palsy by computer-based video analysis of general movements: a feasibility study*. *Developmental Medicine & Child Neurology*, 2010. **52**(8): p. 773-778.
30. Adde, L., et al., *Using computer-based video analysis in the study of fidgety movements*. *Early Human Development*, 2009. **85**(9): p. 541-547.
31. Raghuram, K., et al., *Automated movement analysis to predict motor impairment in preterm infants: a retrospective study*. *Journal of Perinatology*, 2019.
32. Karch, D., et al., *Quantification of the segmental kinematics of spontaneous infant movements*. *Journal of biomechanics*, 2008. **41**(13): p. 2860-2867.
33. Philippi, H., et al., *Computer-based analysis of general movements reveals stereotypies predicting cerebral palsy*. *Developmental Medicine & Child Neurology*, 2014. **56**(10): p. 960-967.
34. Kanemaru, N., et al., *Specific characteristics of spontaneous movements in preterm infants at term age are associated with developmental delays at age 3 years*. *Developmental Medicine & Child Neurology*, 2013. **55**(8): p. 713-721.
35. Jordan, M.I. and T.M. Mitchell, *Machine learning: Trends, perspectives, and prospects*. *Science*, 2015. **349**(6245): p. 255-260.
36. Woolfenden, S., et al., *Developmental vulnerability – don't investigate without a model in mind*. *Child: Care, Health and Development*, 2015. **41**(3): p. 337-345.
37. Walker, S., et al., *Child Development 1: Inequality in early childhood: risk and protective factors for early child development*. *The Lancet*, 2011. **378**(9799): p. 1325-38.
38. Maggi, S., et al., *The social determinants of early child development: An overview*. 2010: Melbourne, Australia. p. 627-635.
39. Bronfenbrenner, U. and S.J. Ceci, *Nature–Nurture Reconceptualized in Developmental Perspective: A Bioecological Model*. *Psychological Review*, 1994. **101**(4): p. 568-586.
40. von Elm, E., et al., *The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies*. *Annals of Internal Medicine*, 2007. **147**(8): p. 573-577.
41. Cohen, J.F., et al., *STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration*. *BMJ Open*, 2016. **6**(11): p. e012799.
42. Hagemann, E., et al., *The ORIGINS project*, in *Pre-emptive medicine: Public health aspects of developmental origins of health and disease, Current topics in environmental health and preventive medicine*, Sata F, Fukuoka H, and H. M, Editors. 2019, Springer Nature: Singapore. p. 99 - 116.
43. Silva, D.T., et al., *Introducing the ORIGINS project: a community-based interventional birth cohort*. *Rev Environ Health*, 2020.
44. Cheong, J.L. and L.W. Doyle, *Increasing rates of prematurity and epidemiology of late preterm birth*. *Journal of paediatrics and child health*, 2012. **48**(9): p. 784-788.
45. The Australian Cerebral Palsy Register, G., et al., *Australian Cerebral Palsy Register Report 2016*. 2016, Unpublished.
46. Kwong, A., et al., *The Baby Moves smartphone app for General Movements Assessment: Engagement amongst extremely preterm and term-born infants in a state-wide geographical study*. *Journal of Paediatrics and Child Health*, 2018.

- 1
- 2
- 3
- 4 47. Ustad, I.T., et al., *Validity of the General Movement Optimality List in Infants Born Preterm*. *Pediatric Physical Therapy*, 2017. **29**(4): p. 315-320.
- 5
- 6 48. LeBreton, J.M. and J.L. Senter, *Answers to 20 Questions About Interrater Reliability and Interrater Agreement*. *Organizational Research Methods*, 2008. **11**(4): p. 815-852.
- 7
- 8
- 9 49. Morais, R., et al., *Learning regularity in skeletal trajectories for anomaly detection in videos*, in *Conference on Computer Vision and Pattern Recognition 2019: Long Beach, California*. p. 11996-12004.
- 10
- 11
- 12 50. Venkatesh, S., P. Vellank, and V. Le, *Accuracy of machine scoring of fidelity movements from high risk infant populations*. Cerebral Palsy Alliance: New South Wales.
- 13
- 14
- 15
- 16 51. Bayley, N. and G.P. Aylward, *Bayley Scales of Infant and Toddler Development*. 4th Ed. ed. 2019, San Antonio: Harcourt.
- 17
- 18 52. Johnson, S., T. Moore, and N. Marlow, *Using the Bayley-III to assess neurodevelopmental delay: which cut-off should be used?* *Pediatric Research*, 2014. **75**(5): p. 670-674.
- 19
- 20
- 21 53. Moore, T., et al., *Relationship between Test Scores Using the Second and Third Editions of the Bayley Scales in Extremely Preterm Children*. *The Journal of Pediatrics*, 2012. **160**(4): p. 553-558.
- 22
- 23
- 24
- 25 54. Anderson, P., et al., *Underestimation of developmental delay by the new Bayley-III scale*. *Archives of Pediatric and Adolescent Medicine*, 2010. **164**(4): p. 352 - 356.
- 26
- 27
- 28 55. Smaldone, A., A. Tsimicalis, and P. Stone, *Measuring resource utilization in patient-oriented comparative effectiveness research: A psychometric study of the Resource utilization questionnaire*. *Research and Theory for Nursing Practice: An international journal*, 2011. **25**(2): p. 80-106.
- 29
- 30
- 31 56. Al-Janabi H, Flynn TN, and C. J, *Estimation of a preference-based carer experience scale*. *Medical Decision Making*, 2011. **31**: p. 458 - 468.
- 32
- 33
- 34 57. Lavis, J.N., et al., *How can research organizations more effectively transfer research knowledge to decision makers?* *Milbank Q*, 2003. **81**(2): p. 221-48, 171-2.
- 35
- 36
- 37
- 38 58. Ellen, M.E., et al., *Determining research knowledge infrastructure for healthcare systems: a qualitative study*. *Implementation Science*, 2011. **6**(1): p. 60.
- 39
- 40
- 41 59. Boote, J., R. Telford, and C. Cooper, *Consumer involvement in health research: a review and research agenda*. *Health Policy*, 2002. **61**(2): p. 213-36.
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60



45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Caption : Study assessment timeline. GMA: General Movement Assessment. GMOS: General Movement
Optimality Score. MOS: Motor Optimality Score. EI: Early Intervention

190x300mm (96 x 96 DPI)